Wound Management Formulary (Adults) and Guidance Document

<table>
<thead>
<tr>
<th>Reference No:</th>
<th>936</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version:</td>
<td>3</td>
</tr>
<tr>
<td>Author:</td>
<td>Kerry Carmichael – Tissue Viability Nurse</td>
</tr>
<tr>
<td>Second Author:</td>
<td>Sherrie Reading – Tissue Viability Nurse</td>
</tr>
<tr>
<td>First Issued On:</td>
<td>30th June 2019</td>
</tr>
<tr>
<td>Latest Issue Date:</td>
<td>10th August 2021</td>
</tr>
<tr>
<td>Review Date:</td>
<td>31st July 2023</td>
</tr>
<tr>
<td>Referenced Documents:</td>
<td>CHCP Lower Limb Compression Formulary City Health Care Partnership CIC</td>
</tr>
<tr>
<td></td>
<td>British National Formulary (BNF) <a href="http://www.bnf.org">www.bnf.org</a></td>
</tr>
<tr>
<td></td>
<td>See Section 10</td>
</tr>
<tr>
<td>Ratified By:</td>
<td>CHCP Therapeutics and Pathway Group</td>
</tr>
<tr>
<td>Distribution:</td>
<td>MyCompliance / Team meetings</td>
</tr>
</tbody>
</table>

### Document Revisions

<table>
<thead>
<tr>
<th>Date</th>
<th>Author</th>
<th>Nature of Change</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2021</td>
<td>Kerry Carmichael</td>
<td>Full Review</td>
<td></td>
</tr>
</tbody>
</table>

This document can be found on CHCPs Document Management System (My Compliance) 
Please make sure you use the most current version.
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>INTRODUCTION .................................................................................</td>
<td>3</td>
</tr>
<tr>
<td>2.</td>
<td>PURPOSE ......................................................................................</td>
<td>3</td>
</tr>
<tr>
<td>3.</td>
<td>SCOPE .........................................................................................</td>
<td>4</td>
</tr>
<tr>
<td>4.</td>
<td>EQUALITY, DIVERSITY &amp; INCLUSION ...............................................</td>
<td>4</td>
</tr>
<tr>
<td>5.</td>
<td>ABBREVIATIONS &amp; DEFINITIONS .....................................................</td>
<td>4</td>
</tr>
<tr>
<td>6.</td>
<td>PROCESS .......................................................................................</td>
<td>4-5</td>
</tr>
<tr>
<td>6.1.</td>
<td>Guidelines to Generic Wound Care Range .......................................</td>
<td>6-7</td>
</tr>
<tr>
<td>6.2.</td>
<td>Wound Dressing Formulary ................................................................</td>
<td>8-19</td>
</tr>
<tr>
<td>6.3.</td>
<td>Compression therapy formulary ..................................................</td>
<td>20</td>
</tr>
<tr>
<td>6.4.</td>
<td>Wound Assessment and Clinical Reasoning Process SOP ......................</td>
<td>20</td>
</tr>
<tr>
<td>6.5.</td>
<td>Wound Infection Framework ......................................................</td>
<td>20</td>
</tr>
<tr>
<td>6.6.</td>
<td>Cleansing Protocol .......................................................................</td>
<td>20</td>
</tr>
<tr>
<td>6.7.</td>
<td>Exudate Management Pathway .....................................................</td>
<td>21</td>
</tr>
<tr>
<td>6.8.</td>
<td>Summary .......................................................................................</td>
<td>21</td>
</tr>
<tr>
<td>7.</td>
<td>TRAINING REQUIREMENTS ..................................................................</td>
<td>22</td>
</tr>
<tr>
<td>8.</td>
<td>APPROVAL ......................................................................................</td>
<td>22</td>
</tr>
<tr>
<td>9.</td>
<td>REVIEW ..........................................................................................</td>
<td>22</td>
</tr>
<tr>
<td>10.</td>
<td>REFERENCES ...................................................................................</td>
<td>22</td>
</tr>
<tr>
<td>11.</td>
<td>RECOMMENDED READING ..................................................................</td>
<td>23</td>
</tr>
<tr>
<td>12.</td>
<td>FURTHER READING ..........................................................................</td>
<td>23-25</td>
</tr>
<tr>
<td>13.</td>
<td>Appendix 1 Wound Infection Framework ........................................</td>
<td>26-27</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

This Wound Management Formulary and guidance document is designed to support clinicians employed by CHCP CIC in their assessment and management of wounds by ensuring that their choice of dressing provides the optimum wound healing environment. The information contained within this document is to be used for patients registered with a GP in the Hull CCG and East Riding of Yorkshire CCG areas.

The Wound Management Formulary is aimed at assisting clinicians to provide a consistent approach to wound management, assist in addressing key aspects of wound management and to help direct the clinician to provide the best and most appropriate care thus optimising healing and leading to:

- Improved patient outcomes
- Improved decision making to meet clinical needs
- Optimisation of product use and reduction of waste
- Timely access to appropriate wound management products
- Auditable information to direct education and training requirements
- Effective communication with patients to support self-management where possible

Wound care products detailed within this guidance were collated using a multi-professional approach including the Medicines Management Team, specialist nurses from within the Tissue Viability Service, Clinical Project Lead and Operational Management for the Integrated Nursing and Conditions Service, along with input from the Podiatry Service. This guidance is based upon best practice and the most recent research on wound management.


2. PURPOSE

The purpose of this document is to provide a guide for clinical staff to follow when undertaking the assessment and management of wounds.
3. SCOPE
This document applies to City Health Care Partnership (CHCP) registered staff working in a clinical role that involves the assessment and/or management of wounds.

This guide may be used by other services and organisations both internal and external to CHCP (e.g. 0 – 19 service, Primary Care etc), however each individual team, service or organisation should be aware that the funding for the Integrated Nursing and Conditions Service is provided by the CCGs for adult wound management by CHCP Clinicians as outlined in this formulary.

4. EQUALITY, DIVERSITY & INCLUSION
City Health Care Partnership is committed to developing, supporting and sustaining an inclusive and diverse workforce that is representative of the community that it services. Equally we are committed to the provision of services that respects our increasingly diverse populations and which promotes equality and access and care. Our culture promotes equality and fairness for all in our employment and care and actively discourages any form of discrimination.

5. ABBREVIATIONS & DEFINITIONS
Abbreviations:
CHCP CIC – City Health Care Partnership
INCS – Integrated Nursing and Conditions Service
T.I.M.E – Tissue, Inflammation or Infection, Management of exudate, Edges of the wound

Definitions:
SystmOne (S1) – Electronic Patient Record System

6. PROCESS
The key to successful wound management is a comprehensive patient, limb (if relevant) and wound assessment of each individual patient. A clinician undertaking wound care should include the wound assessment tool T.I.M.E within the assessment process. This tool builds on wound bed preparation and helps to structure the clinician’s approach to wound management. It is an acronym for:
In addition:

- The surrounding skin and psychosocial factors must also be considered.
- Products should only be selected following holistic assessment and consideration of current clinical opinion, and the available evidence of clinical efficacy.
- Details of the management plan must be recorded in the patient’s electronic record on SystmOne.
- Products are to be ordered via Formeo whenever possible.
- When above is not possible products are to be ordered on FP10 by the reviewing CHCP prescribing clinician.
- For wound care products that require ‘Clinical Reasoning’ within the Integrated Nursing and Conditions Service it is the responsibility of the assessing clinician to complete the ‘Clinical Reasoning Questionnaire’ within the patient record and ensure the Wound Assessment / Reassessment 2020 and Clinical Reasoning Process – SOP is followed.

**REMEMBER:**

DRESSINGS ALONE **DO NOT** HEAL A WOUND.

A DRESSING WILL FACILITATE HEALING BY ASSISTING TO PREPARE/MANAGE FACTORS WHICH MAY DELAY/PREVENT HEALING.
### 6.1. Guidelines to Generic Wound Care Range

<table>
<thead>
<tr>
<th>Wound Type</th>
<th>Necrotic</th>
<th>Sloughy</th>
<th>Granulating</th>
<th>Infected</th>
<th>Epithelialising</th>
<th>Fungating/Malodorous</th>
<th>Cavity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Image</strong></td>
<td><img src="image1" alt="Necrotic wound" /></td>
<td><img src="image2" alt="Sloughy wound" /></td>
<td><img src="image3" alt="Granulating wound" /></td>
<td><img src="image4" alt="Infected wound" /></td>
<td><img src="image5" alt="Epithelialising wound" /></td>
<td><img src="image6" alt="Fungating/Malodorous wound" /></td>
<td><img src="image7" alt="Cavity wound" /></td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Necrotic wounds are characterised by black devitalised tissue.</td>
<td>A mixture of dead white cells, dead bacteria, rehydrated necrotic tissue and fibrous tissue.</td>
<td>Granulating tissue usually pink in colour at the base of the wound bed and can have a bumpy (granular) appearance.</td>
<td>Friable, dark red granulation tissue. Increased malodour and pain. Delayed healing. Satellite lesions.</td>
<td>Typified by pink/pale mauve coloured tissue</td>
<td>Has an offensive odour indicating infection or colonisation of bacteria. Often palliative patients may have a fungating wound.</td>
<td>Wound extends to tissues deep into the epidermis and dermis.</td>
</tr>
<tr>
<td><strong>Treatment Aim</strong></td>
<td>To soften and remove necrotic tissue by rehydration and debridement to allow granulation. Do not attempt debridement if arterial insufficiency is suspected. Keep dry and refer vascular assessment</td>
<td>To soften and remove slough by rehydration and debridement.</td>
<td>To maintain ideal environment for granulation.</td>
<td>To control and manage infection. Consider biofilm</td>
<td>To protect epithelialising tissue until established. To promote an ideal environment for epithelialisation and contraction.</td>
<td>To manage odour, bleeding and exudate.</td>
<td>To promote granulation from the base of the wound.</td>
</tr>
</tbody>
</table>

*Wound Bed must be protected with a non-adherent dressing to prevent adherence of other dressings. Antibiotics must be used only when appropriate.*
| NO EXUDATE       | Hydrogels/sheet | Hydrogels/sheet | Low Adherent | Identify wound infection as per Framework:
|                 |                |                |             | Contaminated
|                 |                |                |             | Colonised
|                 |                |                |             | Local Infection
|                 |                |                |             | Spreading Infection
|                 |                |                |             | Systemic
|                 |                |                |             | Treat with the appropriate topical infection management dressing and / or antibiotics
|                 |                |                |             | Film
|                 |                |                |             | Low adherent
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
|                 |                |                |             | Topical Antimicrobial (P)
|                 |                |                |             | Odour Control
|                 |                |                |             | Fibre Dressing
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
| LOW EXUDATE     | Hydrogels/sheet | Hydrogels/sheet | Foam Absorbent Dressing | Low Adherent
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
|                 |                |                |             | Low adherent
|                 |                |                |             | Fibre Dressing
|                 |                |                |             | Alginate
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
|                 |                |                |             | Infection Management
|                 |                |                |             | Odour Control
|                 |                |                |             | Fibre Dressing
|                 |                |                |             | Alginate
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
| MODERATE TO HIGH EXUDATE | Fibre Dressing Foam or Absorbent Dressing | Fibre Dressing Foam or Absorbent Dressing | Fibre Dressing Alginate Foam | Foam
|                 |                |                |             | Absorbent Dressing
|                 |                |                |             | Low adherent
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing
|                 |                |                |             | Infection Management
|                 |                |                |             | Odour Control
|                 |                |                |             | Fibre Dressing
|                 |                |                |             | Alginate
|                 |                |                |             | Foam
|                 |                |                |             | Absorbent Dressing

Patients must have an individual holistic assessment followed by a comprehensive wound assessment to develop a treatment plan that is patient specific for their needs. All wounds must be re-assessed minimum every 4 weeks or when there are any changes in the wound. These assessments are the key to a successful outcome for patients who have acute or chronic wounds. It is the clinician’s responsibility to identify intrinsic factors e.g. diabetes/ischaemia/compliance, on any wound that is acute/chronic or complex as these will influence the potential for that wound to heal. Realistic goals and outcomes must be discussed. Patient who have an identified wound infection clinicians must refer to the Wound Management Framework and have supporting evidence in the patient record on the use of products, discontinuing products and why products have not been used.
## 6.2. Wound Dressing Formulary

**ABSORBENT DRESSINGS:**
For exudating wounds and can be used as a primary or secondary dressing. 
To be used in conjunction with the CHCP Exudate Management Pathway - see Appendix 4

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFT PORE</td>
<td>Island dressing</td>
<td>Superficial and surgical wounds with no - low exudate levels</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZETUVIT</td>
<td>Absorbent pad</td>
<td>Wet wounds with low-moderate exudate levels</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KERRAMAX CARE</td>
<td>Super Absorbent pad</td>
<td>Wet wounds with moderate exudate levels</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>CUTIMED SORBION SACHET S</td>
<td></td>
<td>Suitable for high levels of exudate</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>CUTIMED SORBION SACHET XL</td>
<td></td>
<td>Suitable for high levels of exudate</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

**ALGINATE DRESSINGS:**
Not to be used on dry wounds. Assists with haemostasis. Cut to size of wound bed to avoid maceration and excoriation to surrounding skin.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>KALTOSTAT</td>
<td>Calcium-sodium alginate dressing</td>
<td>Bleeding wounds Sloughy wounds Moderate to high exudate levels</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**FIBRE DRESSINGS:**
Assists with managing exudate and debridement of wet slough. These products expand once in contact with wound exudate and turns into a gel form which helps maintain a moist environment for optimal wound healing.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTIVHEAL AQUAFIBER EXTRA</td>
<td>Fibre dressing which contains calcium ions. Can remain in situ for up to 7 days depending on exudate levels.</td>
<td>Wounds with moderate – high exudate levels. This dressing can act as a haemostat to control minor bleeding in superficial wounds. To hydrate and debride</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DURAFIBER</td>
<td>A highly absorbent fibre dressing composed of a blend of cellulose-based fibres. Can remain in situ for up to 7 days depending on exudate levels.</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FILM DRESSINGS:**
Contains no absorbent properties. Film dressings are made up of a thin polyurethane membrane covered by a layer of acrylic adhesive.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDRO-FILM</td>
<td>Vapour-permeable adhesive film dressing with a high moisture vapour transmission rate.</td>
<td>Hydrofilm is primarily used for securing secondary dressings such as absorbent pads.</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**FOAM DRESSINGS:**
Aims to prevent dressing-related trauma, manage exudate, and minimize dressing discomfort. Can be used as a primary or secondary dressing for chronic and acute wounds.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLEVYN ADHESIVE BORDER</td>
<td>Foam adhesive consisting of 3 layers; an adhesive wound contact layer, absorbent hydro cellular pad and a waterproof outer film.</td>
<td>For chronic and acute wounds with low to moderate exudate levels. Not suitable for dry wounds and fragile skin.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALLEVYN ADHESIVE GENTLE BORDER</td>
<td>As above but contains a border with a lower adhesive level.</td>
<td>For wounds with low to moderate exudate levels. Aims to avoid trauma to fragile skin.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALLEVYN NON-ADHESIVE FOAM</td>
<td>A sterile, non-adhesive hydro cellular dressing</td>
<td>For wounds with low – moderate exudate levels.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTIVHEAL FOAM HEEL DRESSING</td>
<td>Non-adhesive dressing made up of low friction backing, soft absorbent foam and a wound contact layer. Shaped to fit heels.</td>
<td>For wounds with low – moderate exudate levels.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUPRASORB P SILICONE</td>
<td>Made up of a wound contact layer, polyurethane absorbent foam, a non-woven distribution layer, a superabsorbent polymer core and an external film backing.</td>
<td>For wounds with low to moderate exudate levels.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**HYDROCOLLOID DRESSINGS:**
Waterproof and self-adhesive. Promotes granulation. Enables rehydration and autolytic debridement of dry, necrotic, or sloughy wounds.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTIVHEAL HYDROCOLLOID</td>
<td>This dressing is made up of a thin layer of hydrocolloid laminated to a highly breathable film. Contains a mixture of synthetic polymers and hydrophilic powders, with a high moisture vapor transmission rate film backing.</td>
<td>For wounds with low-moderate exudate levels.</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HYDROGELS/SHEETS:**
High (90%) water content dressings. Designed to hydrate wounds, re-hydrate eschar and aid in autolytic debridement.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTIVHEAL HYDROGEL</td>
<td>This dressing is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound and encourages moist wound healing through autolytic debridement.</td>
<td>Dry, necrotic, and sloughy wounds Dressing will increase moisture due to autolytic debridement.</td>
</tr>
<tr>
<td>KERRALITE COOL</td>
<td>This dressing is made up of a fluid-repellent hydrogel contact layer and a polyurethane film outer layer. This dressing can assist in autolytic debridement by hydration of necrotic and sloughy tissue and for absorption of exudate.</td>
<td>Necrotic, sloughy, and painful wounds. Dressing will increase moisture due to autolytic debridement. <strong>Not suitable for:</strong> full-thickness wounds; heavily bleeding wounds; third-degree burns; or as a covering for deep, narrow cavities or sinuses.</td>
</tr>
</tbody>
</table>
**LOW ADHERENT/ATRAUMATIC DRESSINGS:**

*Aim to prevent trauma to granulating/friable wounds.*

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRAUMAN</td>
<td>Non-adherent, polyester mesh wound contact layer.</td>
<td>Non adherent dressing removal; promotion of healthy granulation tissue.</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTIVHEAL SILICONE WOUND CONTACT LAYER</td>
<td>Non-adherent. The silicone aspect allows atraumatic removal of the dressing.</td>
<td>Atraumatic removal. Suitable for painful and fragile wounds.</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>BACTIGRAS (For Podiatry Use Only)</td>
<td>Medicated paraffin gauze containing chlorhexidine acetate 0.5%.</td>
<td>Suitable for: Dry fissures on feet</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

**ODOUR CONTROL DRESSINGS:**

*Assists with reducing wound odour.*

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODOLOCK</td>
<td>Charcoal dressing which absorbs odour. This dressing is composed of pure activated carbon encased in a non-woven nylon envelope.</td>
<td>Malodorous wounds such as fungating carcinomas and ulcerative, traumatic and surgical wounds. <strong>DO NOT APPLY</strong> if the patient has a sensitivity to nylon. This dressing should never be cut as particles of activated charcoal may enter the wound and cause discoloration.</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### PROTEASE MODULATING MATRIX DRESSINGS:

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>URGOSTAR T CONTACT</td>
<td>Flexible non occlusive contact layer.</td>
<td>Can be used on diabetic foot ulcers, venous leg ulceration, pressure ulcers and long-standing acute wounds. <strong>DO NOT USE</strong> On infected or critically colonised wounds, cancerous wounds, fistulas, which may reveal a deep abscess.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>URGOSTAR T PLUS WITH BORDER</td>
<td>A superabsorbent layer, and a silicone border with waterproof backing. (Adhesive)</td>
<td>Non-healing wounds to aid with any stage of wound healing (from de-sloughing to complete healing wounds including leg ulcers, diabetic foot ulcers, pressure ulcers, and long-standing acute wounds.) <strong>DO NOT USE</strong> on heavily bleeding wounds, cancerous wounds, wounds that may reveal a deep abscess or infected wounds.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>URGOSTAR T PLUS</td>
<td></td>
<td>This product should be used as 1st Line choice for Diabetic Foot Ulcers under Podiatry care</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TOPICAL NEGATIVE PRESSURE (TNP) THERAPY:

*TNP* is a system that uses controlled negative pressure (vacuum) to help promote wound healing.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>PICO SINGLE USE NEGATIVE PRESSURE WOUND THERAPY SYSTEM</td>
<td>Single-use, portable negative pressure wound therapy (NPWT) system. The lightweight pump delivers negative pressure of -80mmHg and provides therapy for up to 7 days.</td>
<td>Suitable for wounds such as chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts, and surgically closed incision sites. <strong>DO NOT USE</strong> on patients with malignancy in the wound bed or wound margins (except in palliative care to improve quality of life under the direction of a specialist); previously confirmed or untreated osteomyelitis; non-enteric and unexplored fistulas; necrotic tissue with eschar present; exposed arteries, veins, nerves or organs; exposed anastomotic sites; emergency airway aspiration; pleural, mediastinal or chest tube drainage; and surgical suction.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
RENASYS NEGATIVE PRESSURE WOUND THERAPY (NPWT):

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>RENASYS TOUCH CONSUMABLE</td>
<td>Canister kit Dressing kit (foam and gauze) Softport dressing kit Y connector Renasys Gauze filler</td>
<td>Can be used on wounds such as chronic, acute, traumatic, sub-acute and dehisced wounds; ulcers (such as pressure or diabetic); partial-thickness burns; flaps and grafts. Suitable for deep wounds with moderate – high exudate levels. Designed to provide individualized negative pressure wound therapy for highly complex wounds. <strong>DO NOT USE:</strong> on necrotic tissue with eschar present; untreated osteomyelitis; malignancy in wound (except palliative care to enhance quality of life); exposed arteries, veins, nerves or organs; non-enteric and unexplored fistulas; anastomotic sites.</td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
</tbody>
</table>
### INFECTION MANAGEMENT – ANTIMICROBIALS WITH A PHYSICAL MODE OF ACTION:

*To be used in conjunction with the CHCP Wound Infection Framework - see Appendix 2*

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>CUTIMED SORBACT</td>
<td>Sorbact-technology-coated hydrophobic antimicrobial dressing designed to bind bacteria.</td>
<td>Superficial wounds, traumatic wounds, post op or dehisced, leg ulcers. Suitable for fungal infections in the groin, skin folds, or between digits.</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>CUTIMED SORBACT GEL</td>
<td>DO NOT USE with ointments and creams as the binding effect is impaired.</td>
<td>Superficial wounds, traumatic wounds, post op or dehisced, leg ulcers.</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>CUTIMED SILTECT SORBACT</td>
<td>Hydrophobic, microbial-binding foam dressing</td>
<td>Superficial wounds, traumatic wounds, post op or dehisced, leg ulcers.</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>MEDIHONEY GEL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>MEDIHONEY HCS</td>
<td>Medical grade manuka honey.</td>
<td>Superficial wounds, burns, pressure ulcers leg and foot ulcers, doner and recipient graft sites. Can be used on devilised tissue (HSC 1st &amp; 2nd degree burns)</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
## INFECTION MANAGEMENT - ANTIMICROBIALS CONTAINING SILVER:
To be used in conjunction with the CHCP Wound Infection Framework – see Appendix 2

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTICOAT FLEX 3</td>
<td>Low adherent dressing. Can moisten for drier wounds. Should be left in place for 3 days</td>
<td>First and second-degree burns. Grafts, Surgical sites, Venous ulcers, Pressure ulcers Diabetic ulcers</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>ACTICOAT FLEX 7</td>
<td>As above but leave in place for 7 days</td>
<td>First and second-degree burns Grafts, Surgical Sites, Venous ulcers, Pressure ulcers Diabetic</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>AQUACEL AG</td>
<td>Designed to manage 3 key local barriers to healing</td>
<td>Leg ulcers, pressure ulcers, diabetic foot ulcers, donor sites, surgical wound, 1st &amp; 2nd degree burns, exudate management in fungating wounds</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

## INFECTION MANAGEMENT - OTHER ANTIMICROBIAL DRESSINGS:
To be used in conjunction with the CHCP Wound Infection Framework – see Appendix 2

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DRESSING TYPE</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>IODOSORB OINTMENT</td>
<td>Cadexomer iodine-based dressing use IODOSORB within the guidelines of the prescribing information (up to a maximum of 150g a week)</td>
<td>Removes excess exudate and slough. Can be used under compression.</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>IODOFLEX DRESSING</td>
<td></td>
<td>Removes excess exudate and slough. Can be used under compression.</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
### INADINE
- **Product**: Povidine iodine-based dressing
- **Application**: BIOFILM MANAGEMENT
- **Indications**: Ulcers, minor burns and minor traumatic skin injuries, Rubefacient in chilblains

### FLAMINAL FORTE
- **Product**: Alginate gels
- **Application**: BIOFILM MANAGEMENT
- **Indications**: Wet wounds
- **Clinical Reasoning**: Can be used on acute and chronic wounds

### FLAMINAL HYDRO
- **Note**: Products NOT available on Formeo - need to be ordered on FP10
- **Indications**: Dry Wounds

### OTHER RELEVANT PRODUCTS:
*All products to be ordered via the Formeo platform*

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>PRODUCT</th>
<th>TYPE OF WOUND</th>
<th>FIRST LINE</th>
<th>SECOND LINE</th>
<th>CLINICAL REASONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleansing Agents</td>
<td>IRRIPOD - sterile saline pods</td>
<td>Wet wounds</td>
<td>💚</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OCTENILIN - Antimicrobial Cleansing Agent</td>
<td>Wet wounds</td>
<td>❌</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debridement Pad</td>
<td>DEBRICLEAN</td>
<td>Supports the mechanical debridement process</td>
<td>💚</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin Protectors</td>
<td>CUTIMED PROTECT</td>
<td>Cream, foam and spray form available</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAPES and FIXATION</td>
<td>MICROPORE SURGICAL TAPE</td>
<td>✔️</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CliniTape Clear – latex free</td>
<td>For use when sensitivity to latex present</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEFIX</td>
<td>✔️</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TUBULAR BANDAGE (ELASTICATED)</td>
<td>EESIGAUZ Cotton Stockinette All sizes for legs/arms/toes/finger</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOUND CARE ACCESSORIES</td>
<td>SOFTDRAPE DRESSING PACKS</td>
<td>✔️</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALVITA NURSEIT DRESSING PACKS</td>
<td>✔️</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DRESSIT ASEPTIC PACKS</td>
<td>Only if other packs not available</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6.3. Compression therapy formulary
For all products relating to compression therapy please see: CHCP Lower Limb Compression Formulary City Health Care Partnership CIC, available on MyCompliance.

6.4. Wound Assessment and Clinical Reasoning Process SOP
All clinicians within the Integrated Nursing and Conditions Service must adhere to the Wound Assessment / Reassessment 2020 and Clinical Reasoning Process – SOP when using this Wound Management Formulary guidance document.

All wounds should be reviewed every 4 weeks as a minimum by a clinician with appropriate skills. Unstageable and suspected DTI ulcers need to be reviewed on a weekly basis to help identify a definite PU category.

Any changes in the management plan must be supported by a TIME assessment of the wound/s and a rationale provided within the patient record.

6.5. Wound Infection Framework
see Appendix 1

The Wound Infection Framework is designed to support all clinicians with achieving the principles of antimicrobial stewardship, including the use of the TWO WEEK CHALLENGE to help address issues with antimicrobial resistance.

Wounds which are dressed with a product identified on the Wound Infection Framework guidance should be reviewed every 2 weeks as a minimum.

Any changes in the management plan must be supported by a TIME assessment of the wound(s) and a rationale provided.

6.6. Cleansing Protocol
see Appendix 2

The purpose of wound cleansing is to remove debris/remnants of previous dressings/exudate/emollients from the wound bed and surrounding skin and to aid in the management of biofilm and wound infection.
Wounds which are on a healthy trajectory to healing with healthy granulation/epithelial tissue may not require routine cleansing.

A skin management regime should be included in the care plan for peri wound skin/surrounding skin/limb when required.

In addition, it is important that gangrenous wounds should be kept dry.

6.7. Exudate Management Pathway
see Appendix 3

The purpose of the Exudate Management Pathway is support clinicians in adopting a **STEP UP** and **STEP DOWN** approach to the choice of absorbent used to manage wound exudate. Appropriate management of exudate assists in the prevention of the breakdown to the tissue and skin surrounding a wound due to excoriation and / or maceration.

6.8. Summary
This Wound Management formulary supports the clinical decision-making process when selecting an appropriate wound product, following a holistic assessment of the patient.

**Areas to consider:**

- Practitioners should avoid multiple dressing use at any one time, unless specifically indicated.
- The practitioner should adhere to the manufacturer’s guidelines when utilising products.
- The aetiology of the wound should always be established prior to the selection of a dressing
- For guidance regarding wound swabbing refer to Wound Infection Framework – see Appendix 1
- Use of any antimicrobial product must be supported by following the Wound Assessment / Reassessment 2020 and Clinical Reasoning Process – SOP
• Consider any over the counter or home remedies the patient may be utilising.
• Non-medical prescribers are professionally accountable for their prescribing decision, including actions and omissions. All registered nurses are personally accountable for their practice ensuring that they: Prioritise people, Practise effectively, Preserve safety and Promote professionalism (NMC 2018).

7. TRAINING REQUIREMENTS
Any clinician undertaking wound care should have undertaken and received appropriate wound care training and be deemed competent prior to using this document.

8. APPROVAL
This guidance has been reviewed and approved by the stakeholders identified on the document checklist submitted to the Therapeutics and Pathways Group which reviewed the checklist and ratified this document.

9. REVIEW
This guidance will be reviewed every 2 years or sooner if prompted by changes in legislation or best practice requirements.

10. REFERENCES
References:
CHCP Lower Limb Compression Formulary City Health Care Partnership CIC
National Institute for Health and Care Excellence
National Prescribing Centre: www.guidelinesinpractice.co.uk/the-national-prescribing-centre/305502.article
Standards for prescribers: https://www.nmc.org.uk/standards/standards-for-post-registration/standards-for-prescribers/

Wound management products and elasticated garments: [https://bnf.nice.org.uk/wound-management/](https://bnf.nice.org.uk/wound-management/)

Wound UK: Website that has Best Practice Statements/Journal and Education that is wound related: [https://www.wounds-uk.com/](https://www.wounds-uk.com/)

Wound Care Handbook: [https://www.woundcarehandbook.com/](https://www.woundcarehandbook.com/)

British National Formulary (BNF) [www.bnf.org](http://www.bnf.org)

11. RECOMMENDED READING

City Health Care Partnership CIC Protocols on:

Assessment and Management of wounds in the Community Guidance Document

12. FURTHER READING

For further information regarding the variety of products available within this formulary:


- **AQUACEL® Ag+**: [https://www.convatec.co.uk/products/pc-wound-skin-tear/aquacel-ag-plus-dressings](https://www.convatec.co.uk/products/pc-wound-skin-tear/aquacel-ag-plus-dressings)


- **CLINITAPE CLEAR (Latex Free)**: [https://www.clinisupplies.co.uk/products/24/CliniTape-CLEAR-Surgical-Tape](https://www.clinisupplies.co.uk/products/24/CliniTape-CLEAR-Surgical-Tape)


- **FLAMINAL FORTE**: [www.crawfordhealthcare.com/woundcare/flaminal/flaminal-forte](http://www.crawfordhealthcare.com/woundcare/flaminal/flaminal-forte)

- **FLAMINAL HYDRO FORTE**: [www.crawfordhealthcare.com/woundcare/flaminal/flaminal-forte](http://www.crawfordhealthcare.com/woundcare/flaminal/flaminal-forte)

- **IRRIPOD**: [https://www.cdmedical.co.uk/products/irripod/](https://www.cdmedical.co.uk/products/irripod/)


- **MICROPORE SURGICAL TAPE**: [http://multimedia.3m.com/mws/media/784590O/3m-medical-tapes-full-line-catalog.pdf?&fn=70-2010-8488-9.pdf/?WT.mc_id=C3SD_Twitter_MedicalTape](http://multimedia.3m.com/mws/media/784590O/3m-medical-tapes-full-line-catalog.pdf?&fn=70-2010-8488-9.pdf/?WT.mc_id=C3SD_Twitter_MedicalTape)
- **MEDIHONEY**: [http://www.dermasciences.com/medihoney](http://www.dermasciences.com/medihoney)


- **ODOLOCK**: [http://www.systagenix.co.uk/our-products/manage-odour/odolockandtrade-395](http://www.systagenix.co.uk/our-products/manage-odour/odolockandtrade-395)


- **SOFTDRAPE DRESSING PACK**: [https://www.richardsonhealthcare.com/softdrape/](https://www.richardsonhealthcare.com/softdrape/)

For all other wound care products, please see [https://www.woundcarehandbook.com/](https://www.woundcarehandbook.com/)
13. Appendix 1 Wound Infection Framework

**Wound Infection Framework**

---

**Contamination**
- All wounds acquire microorganisms.
- If suitable nutritive and physical conditions are not available for each microbial species, or they are not able to successfully evade host defences, they will not multiply or persist; their presence is only transient and wound healing is not delayed.

**Colonisation**
- Microbial species successfully grow and divide, but do not cause damage to the host or initiate wound infection.

**Vigilance Required**
- No topical antimicrobial required.
  - Do not swab.
  - Cleanse following ‘Cleansing Protocol’ Optimise wound healing with debridement and dressing choice using ‘Tissue Type Guide’.
  - Monitor wound progress at each dressing change:
    - If deterioration or signs of infection noted reassess and change treatment plan accordingly.
    - If no progress after 2 weeks reassess wound and treatment plan.
    - If wound progressing continue with treatment plan and formally reassess wound at least every 4 weeks.

**Local Infection**
- Hypersensitive reaction.
- Local warming.
- Swelling.
- Purulent discharge.
- Delayed wound healing beyond expectations.
- New or increasing pain.
- Increasing malodour.

**Spreading Infection**
- Extending induration +/.
- Erythema.
- Local warmth.
- Swelling.
- Purulent discharge.
- Delayed wound healing beyond expectations.
- New or increasing pain.
- Increasing malodour.

**Systemic Infection**
- Severe sepsis.
- Sepsis shock.
- Organ failure.
- Death.

**Intervention Required**
- Physical mode of action antimicrobial dressing.
  - Or:
  - Other topical antimicrobial dressing if clinically indicated.
  - Do not swab.
  - Debride and cleanse as per ‘Cleansing Protocol’.
  - Follow the TWO WEEK CHALLENGE principles below.

**TWO WEEK CHALLENGE**
- Dressings with a physical mode of action or antimicrobial dressings are recommended to be used for a minimum of two weeks duration.
- Complete “Clinical Reasoning Questionnaire” each time dressing is commenced / reviewed.
- After every two weeks, reassess the wound and either:
  1. Discontinue if signs and symptoms of infection have resolved.
  2. Continue with physical mode of action dressing / antimicrobial agent if wound is progressing but there are still signs and symptoms of infection and complete clinical reasoning questionnaire.
  3. Consider alternative physical mode of action dressing / antimicrobial agent if no improvement.
  4. After 4 weeks of continuous use of physical mode of action dressing / antimicrobial agent a referral to the Tissue Viability Service must be made.

---

**BIOFILM - see reverse**

Increasing Microbial Virulence / Or Numbers

---

**chcp**

---

**Version:** 1  **Ref:**  **Owner:** Kerry Carmichael  **Page 26 of 30**

**Issued:** 10.08.2021  **Title:** Wound Management Formulary (Adults) and Guidance Document
**BIOFILM**

Criteria indicative of potential biofilm:
- Failure of antibiotic / antimicrobial treatment
- Recurrence of delayed healing on cessation of antibiotic treatment
- Delayed healing despite optimal wound management and health support
- Increase exudate / moisture
- Low level chronic inflammation
- Low level erythema
- Poor granulation / fragile hypergranulation
- Covert (subtle) signs of infection

**Proactive Treatment of Biofilm:**
- Do not swab
- Ensure the following is undertaken at least twice every week:
  1. Break up and remove the biofilm following the 'cleaning protocol' to include:
     - Vigorous / active cleansing or debridement of the wound bed to remove the devitalised tissue, debris and biofilm
     - Removal of necrosis, serous crusts from wound edges and margins
     - Refashion overhanging, raised or rolled wound edges to ensure the skin edges align with the wound bed to facilitate epithelial advancement
     - Cleansing of periwound skin to manage and remove hyperkeratoses, dead skin cells, callus and remnants of emollients, to include leg washing and skin care
  2. Reduce biofilm formation:
     - Disrupt and prevent reformation of biofilm using physical mode of action dressing or other suitable antimicrobial dressing with anti-biofilm properties if clinically indicated

**FACTORS ASSOCIATED WITH INCREASED RISK OF WOUND INFECTION**

Assess the patient and their comorbidities, wound(s), skin and environment to identify and manage infection risk factors as below:

**Characteristics of the individual:**
- Poorly controlled diabetes
- Prior surgery
- Radiation or chemotherapy
- Conditions associated with hypoxia and / or poor tissue perfusion (e.g. anaemia, cardiac or respiratory disease, arterial or vascular disease, renal impairment, rheumatoid arthritis, shock)
- Immune system disorders (e.g. acquired immune deficiency syndrome, malignancy)
- Inappropriate antibiotic prophylaxis, particularly in acute woundings
- Protein energy malnutrition
- Alcohol, smoking and drug abuse

**Characteristics of the wound:**
- Contaminated or dirty wounds
- Trauma with delayed treatment
- Pre existing infection or sepsis
- Spillage from gastro intestinal tract
- Penetrating wounds over 4 hours
- Inappropriate hair removal
- Operative factors (e.g. long surgical procedure, hypothermia, blood transfusion)
- Degree of chronicity/duration of wound
- Large wound area
- Deep wound
- Anatomically located near a site of potential contamination (e.g. perineum or scarum)
- Foreign body (e.g. drains, sutures)
- Haematoma
- Necrotic wound tissue
- Impaired tissue perfusion
- Increased exudate or moisture

Optimise individual host response
Reduce wound bacterial load
Promote environmental and general measures

References:
European wound infection continuum 2016
Wound infection in clinical practice. An international consensus
14. Appendix 2 – Cleansing Protocol

Cleansing Protocol: for all Wounds

The purpose of wound cleansing is to remove debris, remnants of previous dressings, exudate and emollients. Wound cleansing will also aid in the management of biofilm and wound infection management. Wounds which are on a healthy trajectory to healing, having healthy granulation and/or epithelial tissue may not require routine cleansing. In addition, a skin management regime should be included in the care plan for peri wound skin, surrounding skin and the whole limb.

<table>
<thead>
<tr>
<th>Product</th>
<th>Usage</th>
<th>Aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potable water</td>
<td>No clinical signs of infection</td>
<td>To remove debris, exudate, remnants of previous dressings and emollients</td>
</tr>
<tr>
<td>Irripod Sterile Normal Saline</td>
<td>48 hrs post op. for diabetic foot ulcers or when exposed underlying structures are visible</td>
<td>NB: Cleansing of the surrounding skin and limb needs to be included as part of a comprehensive care plan</td>
</tr>
</tbody>
</table>
| Octenilin Wound Irrigation Solution | Should be considered for infected wounds and where biofilm is suspected  
Review after 2 weeks of usage | To reduce the bacterial burden within the wound  
To disrupt and aid in removal of biofilm |
| Cutimed® DebriClean Debridement pad | Should be considered for infected / sloughy / necrotic wounds and where biofilm is suspected  
Review after 2 weeks of usage | To disrupt and aid in the removal of biofilm and debridement of the wound  
To remove devitalised tissue, slough, necrosis and bacterial burden from the wound bed To aid in removal of serocrusts and hyperkeratosis |
15. Appendix 3 – Exudate Management Pathway

Exudate Management Pathway

Assess at every dressing change and STEP UP or STEP DOWN to manage exudate levels appropriately, prevent maceration and promote skin health.

Zetuvit

Suitable for low exudate levels where dressing changes are done 1-2 times weekly. If dressing changes are required more than 3x weekly and/or periwound skin is getting macerated change to Kerramax Care Super Absorber.

Kerramax Care

Suitable for moderate to high levels of exudate.

If peri wound skin becomes vulnerable to moisture, increase frequency of visits and consider use of emollient and skin barrier products.

Reassess cause of increased exudate and if daily visits persist change to Cutimed® Sorbion® Sachet S

Make referral to Tissue Viability Nurse

Cutimed® Sorbion® Sachet S

Suitable as a primary or secondary dressing for highly exuding wounds when Zetuvit or Kerramax Care have not managed exudate levels effectively and skin has become macerated.

Can be used daily to prevent maceration if necessary.

If twice daily dressings are needed or maceration occurs change to Cutimed® Sorbion® Sachet XL following further TVN advice prior to commencement

Cutimed® Sorbion® Sachet XL

Suitable as a primary or secondary dressing when Cutimed® Sorbion® Sachet S have failed to manage exudate levels effectively.

Reassess cause of increased exudate and comorbidities

For highly exuding cavity wounds consider other strategies and discuss with TVN

Never layer superabsorbent pads.

Do not use hydrofiber dressings on ‘wet legs’ when no defined wound is evident.

If skin is damaged use a skin protector, as per product guideline, for 28 days to replace hydrolipid layer.

To prevent skin damage use an appropriate skin protector as per product guideline.
Exudate Management Pathway
- Supporting Information

**CAUSES OF EXUDATE**

**Increased bioburden** - High levels of exudate can be associated with increased levels of bacteria. When a wound becomes infected, exudate will increase abruptly as a result of vasodilation and extravasation.

**Devitalised tissue** - Slough and necrosis. Removing the tissue by debridement can result in an increase of exudate.

**Underlying disease** - Co morbidities such as venous disease, lymphoedema, cardiac failure or prolonged immobility can lead to oedema, particularly in the lower leg. Patients with conditions that cause oedema may also have increased wound exudate levels due to fluid overload. These conditions need treatment in order to effectively manage exudate volume.

**Chronic oedema** - If the patient has lymphatic failure, referral to a lymphoedema specialist to establish the cause may be appropriate. Patients with lymphoedema will benefit from compression therapy.

**Heart disease** - Grossly oedematous legs that leak fluid can be a symptom of chronic heart failure; diuretic therapy may be required to treat the heart failure, in conjunction with compression bandaging and leg elevation. Care must be taken to ensure that the cardiac system is not overloaded by a large quantity of fluid being suddenly pushed from the interstitial spaces of the skin into the circulation referral to a heart failure / cardiac specialist may be required.

**TYPES OF EXUDATE**

**Serous** - Clear, amber, thin and watery
 Often considered normal, but may cause further tissue destruction or wound healing failure if excessive

**Serosanguineous** - Clear, pink, thin and watery
 Due to the presence of red blood cells, this indicates capillary damage e.g. Traumatic dressing removal

**Sanguineous** - Thick creamy and bright red
 Due to deeper wounds involving thicker layers of tissue should resolve after first few days of wounding

**Purulent** - Purulent Opaque, milky, sometimes green, Thick may be indicative of bacterial infection